NovaBay Pharmaceuticals, Inc.
NBY
$1.02
$0.088.50%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -6.68% | -21.26% | 338.64% | 70.50% | 31.02% |
| Total Depreciation and Amortization | -61.96% | -57.78% | -42.71% | 0.00% | -3.16% |
| Total Amortization of Deferred Charges | -73.79% | -93.57% | -93.73% | -99.47% | -78.10% |
| Total Other Non-Cash Items | 135.80% | -99.36% | -61.83% | -103.72% | -132.49% |
| Change in Net Operating Assets | 20.97% | -5,950.00% | 401.50% | -21.03% | -653.57% |
| Cash from Operations | 12.71% | -408.45% | 1,476.41% | -19.12% | -466.48% |
| Capital Expenditure | -- | -- | -- | 100.00% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | 100.00% | 100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 33.38% | 100.00% | 12.28% | 100.00% | -37.09% |
| Issuance of Common Stock | -91.77% | -100.00% | -- | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -81.25% | -9,452.63% | -100.00% | -- |
| Cash from Financing | -163.17% | 64.63% | -186.10% | 2,023.08% | 461.87% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -78.64% | -- |
| Net Change in Cash | -12,096.15% | -191.32% | 714.92% | -35.69% | 102.13% |